Skip to content

Catecholaminergic Polymorphic Ventricular Tachycardia 3 C3151463

Published: July 22, 2026Updated: August 25, 2026

A genetic heart rhythm disorder causing dangerously fast heartbeats during exercise or emotional stress. It affects individuals with inherited mutations, often diagnosed in childhood or adolescence. Treatment includes medications, activity restrictions, and sometimes implanted devices to control heart rhythm.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 25, 2026Editorial policy

Key facts at a glance

ICD-10
I78.0
ICD-11
BA00.0
Body system
cardiovascular
Severity
critical
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Chest discomfort or palpitations

Symptoms may be severe and require urgent medical attention.

Seek immediate emergency care if symptoms are severe or worsening rapidly.

!

Exercise-induced syncope

!

Ventricular tachycardia during physical activity

!

Dizziness with emotional stress

!

Palpitations at rest

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Beta-Blocker Therapy

High-dose beta-blockers form the cornerstone of CPVT treatment, significantly reducing catecholamine-triggered arrhythmias by blocking sympathetic stimulation.

medication
2

Disease management and monitoring

Requires immediate emergency medical intervention. Do not delay treatment.

procedure
3

Flecainide Adjunctive Therapy

Class IC antiarrhythmic flecainide added to beta-blocker therapy reduces ventricular ectopic beats and bidirectional tachycardia in CPVT patients.

medication

Additional treatment options

Implantable Cardioverter-Defibrillator (ICD)

ICD implantation for patients with breakthrough cardiac events despite optimal medical therapy, providing life-saving defibrillation for ventricular fibrillation.

surgical

Exercise Restriction

Significant limitation or avoidance of strenuous exercise and competitive sports, as physical exertion is the primary trigger for arrhythmias in CPVT.

lifestyle

Left Cardiac Sympathetic Denervation

Surgical removal of the lower portion of the left stellate ganglion to reduce norepinephrine release and prevent stress-induced arrhythmias.

procedure

When to seek medical help

Recognize when you need immediate medical attention.

Call emergency services (911) immediately

!

Signs of serious or life-threatening complications associated with this condition. Immediate medical evaluation is required.

Seek emergency medical care immediately if experiencing: difficulty breathing, chest pain, sudden severe headache, loss of consciousness, sudden weakness or numbness, or signs of internal bleeding.

Frequently asked questions

Common questions about this topic.

Q

What is Catecholaminergic Polymorphic Ventricular Tachycardia 3 C3151463?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Priori SG, Blom NA, Brugada J, et al. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997-4126.

guideline2022View source →
2

Liu JF, Jaleel A, Antzelevitch C. Catecholaminergic Polymorphic Ventricular Tachycardia: Mechanisms and Management. Circ Arrhythm Electrophysiol. 2020;13(5):e008200.

review2020View source →
3

Roston TM, Vinocur JM, Maginot KR, et al. Clinical Course of Catecholaminergic Polymorphic Ventricular Tachycardia in Children: A Multicenter Prospective Study. J Am Coll Cardiol. 2021;78(1):22-34.

clinical_trial2021View source →
4

Wilde AAM, Amin AS, Ackerman MJ. Calmodulin mutations and catecholaminergic polymorphic ventricular tachycardia: Clinical and functional aspects. Heart Rhythm. 2019;16(11):1659-1665.

Medication Comparisons

Compare medications used to treat Catecholaminergic Polymorphic Ventricular Tachycardia 3 C3151463. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 25, 2026. · Read our editorial policy